FDA slaps Japanese drugmaker with warning letter for stymying inspection

The FDA hit Japanese drug manufacturer Nippon Fine Chemical with a warning letter for obstructing an inspection at its plant last year.

In the letter dated Sept. 26, 2016, which was recently posted on the regulatory agency’s website, the FDA said that during an attempted inspection in Dec. 2015, the firm "limited and/or refused an FDA inspection."

Investigators were limited in their access to the facility located in Takasago City, and at one point an NFC manager directed employees to form a human barrier by standing shoulder to shoulder to block access to areas of the laboratory and equipment used to analyze drugs destined for U.S. distribution.

Whitepaper

Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

Additionally, the company refused to provide copies of documents that included customer complaints of drugs it had manufactured. These complaints said the drugs contained glass, hair, cardboard, metal, product discoloration and in one case, a black spider. The company also prevented the inspector from taking photographs of equipment at the facility.

Nippon Fine Chemical manufactures certain drugs for the Japanese and U.S. markets using the same equipment and processes, and divides lots for distribution between the two.

In early August, the agency placed the company on its Import Alert list, which effectively bans its products from entering the U.S. Until the company complies with FDA inspections, the agency can withhold approval of any new applications or supplements of drugs that are manufactured at the facility.

- check out the warning letter

Related Articles:
FDA cites drug repackager in warning letter 
API repackager in hot water with FDA

Suggested Articles

Higher operating costs were behind a 17% slide in pretax profits last year at Allergan’s Mayo, Ireland, facility that produces Botox.

After a global scare over Zantac contamination, generic metformin could be next in line as regulators test for possible carcinogen contamination.

PCI Pharma Services debuts expansion of its plant in Rockford, Illinois.